Product
Ad26.RSV.PreF-based Vaccine
1 clinical trial
1 indication
Indication
Respiratory Syncytial Virus PreventionClinical trial
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 YearsStatus: Completed, Estimated PCD: 2022-03-28